Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad...
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2024...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.34 | -0.703351261895 | 48.34 | 52.385 | 45.95 | 740483 | 48.87259348 | CS |
| 4 | -6.22 | -11.4717816304 | 54.22 | 58.2 | 45.95 | 674860 | 51.79778431 | CS |
| 12 | 4 | 9.09090909091 | 44 | 58.2 | 41.23 | 660347 | 49.55011497 | CS |
| 26 | 1.64 | 3.53753235548 | 46.36 | 58.2 | 34.5125 | 640458 | 46.50079997 | CS |
| 52 | 38.89 | 426.8935236 | 9.11 | 65.6 | 7.79 | 645672 | 45.41947637 | CS |
| 156 | 29.97 | 166.22296173 | 18.03 | 65.6 | 5.65 | 281138 | 38.10092035 | CS |
| 260 | 14 | 41.1764705882 | 34 | 65.6 | 5.65 | 269940 | 36.92936036 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
